CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers. Jung HR, Oh Y, Na D, Min S, et al. Oncogene 2021;40:3287-3302.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jung HR, Oh Y, Na D, Min S, et al. CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers. Oncogene 2021;40:3287-3302.
PMID: 33846570